ClinicalTrials.gg
Status unknownNCT05193175MOVE-MIUpdated Mar 3, 2023

Effects of Breaking up Sitting Time on Cardiometabolic Risk Markers and Cardiac Function Post Myocardial Infarction

An interventional study of Prolonged sitting in Cardiovascular Diseases, sponsored by University of Bedfordshire. Status unknown at 1 site in United Kingdom. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2023-03-03.

Sponsored by University of Bedfordshire · Not applicable, Interventional, and Prevention

The sponsor has not verified this record recently (last verified Mar 2023), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
18
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Study summary

Cardiovascular Disease (CVD) is one of the greatest causes of mortality and morbidity globally, particularly in middle to high income countries. In the UK alone, it was accountable for 124,641 deaths in 2017. Further to this, CVD contributes to a vast economic burden, costing the National Health Service (NHS) £19billion annually. This is mainly due to a significant number of hospital readmissions following a first cardiac event (198,000 per annum).

Following a cardiac event, an individual is therefore recommended to reduce their risk factors, including lipid profile, smoking status and physical inactivity, to reduce their risk of a secondary event. In healthy individuals, regularly breaking up sitting time reduces cardiometabolic risk markers. The aim of this study is to therefore observe if this effect is replicated in the cardiac population and thus whether breaking up sitting time will reduce the risk of a secondary cardiac event.

Potential participants will be required to meet an inclusion criteria to take part in the study: aged 50 years or above and had a myocardial infarction within the past three months at the time of recruitment to the study.

Participants will be randomised to each condition: 1) uninterrupted sitting; 2) sitting with intermittent standing and 3) sitting with intermittent light physical activity (stepping to a metronome beat). A number of physiological markers will be measured before, during and after each condition and analysed to compare the effectiveness of each condition.

All measurements will be taken at the University of Bedfordshire Sport and Exercise Science Laboratories.

Read the detailed description

Study design A repeated measures, randomised cross over study design will be used. All data collection will take place at the Sport and Exercise Science Laboratories, University of Bedfordshire, Polhill Avenue, Bedford, UK. After a preliminary testing session, participants will complete three, 6-hour experimental conditions in a random order: 1) uninterrupted sitting; 2) sitting interrupted with standing breaks, and 3) sitting interrupted with light intensity stepping breaks. There will be a washout period of at least 72 hours between conditions, as previous research suggests that a single session of exercise can affect blood glucose levels for the following 48 hours (Mikines, et al., 1988). Participants will be randomised to order of condition using computer generated random numbers. This will assign them a trial order using block randomization with balanced block sizes. Participants will be blinded to the trial condition until they arrive on the day of their first and second experimental conditions.

Preliminary testing Patients will first attend a preliminary testing session where they will become accustomed to light intensity stepping on the spot to the beat of a metronome and use of the Borg RPE scale. This will ensure patients are familiar with an intensity that is equivalent to an RPE of 8-11 (very light to light) that will be used in the respective experimental condition. Participants will step to different metronome paces starting at a slow pace and building up gradually every 1-2 minutes until an RPE of 8-11 is found. This imitates the intensity recommended within the warm up of CR, as recommended by BACPR. Height (cm) and weight (kg) will also be measured using a stadiometer (Harpenden 98.602, Holtain Ltd., Crymych) and digital scales (Tanita BWB0800, Tanita Corp., Tokyo, Japan) respectively, to calculate body mass index (kg/m2).

Experimental Protocol Participants will be asked to refrain from any alcohol and caffeine for 24 hours prior to each visit, as well as avoid exercise for 72 hours and complete an overnight fast. This will be explained to them during the preliminary visit. To monitor this, they will be asked prior to participation per visit whether they have fasted/ when they last ate and drank.

Participants will be asked to perform an overnight fast for at least 10 hours before arrival and minimise active travel to the laboratory (e.g. use a car for travel). They will rest for 30 minutes to achieve a steady state before baseline blood pressure (two measures with 2 minutes rest between each and the average taken) and blood samples are taken. Baseline cardiac function measures (global strain, ejection fraction and systolic volume) will be measured using an echocardiogram scan, as well as an electrocardiogram (ECG) to ensure there are no electrical contraindications to the heart which would make the participant unsuitable to complete the study intervention including ST depression / elevation or any arrythmias. Baseline mood and wellbeing measures will then be assessed using questionnaires.

Following baseline measures, a standardised breakfast will be consumed (see meals section below) and participants will then commence the experimental condition. See Figure 1 for schematic of experimental conditions.

The three experimental conditions for this study are:

  1. Uninterrupted sitting for 6 hours.
  2. Sitting interrupted with 5 minutes of static standing every 30 minutes.
  3. Sitting interrupted with 5 minutes of light intensity stepping every 30 minutes using a metronome at the intensity determined during preliminary testing. This replicates active recovery time currently performed in a phase III CR class.

A lunch meal will be provided at 12:00 during each condition. During sitting periods, participants will be able to read books, magazines or newspapers and/or watch TV, DVDs or media streaming services. Participants will be transported to the toilets and food consumption areas using a wheelchair to ensure activity is minimised and standardised between conditions.

Standardised food and water intake Each meal will provide approximately 30% of estimated daily energy requirements. This will be calculated for each individual participant using a prediction equation based on individual's height, weight and gender. Breakfast will consist of bran flakes, whole milk, and a honey and granola bar and will consist of 54% carbohydrate, 34% fat and 12% protein. Lunch will consist of a chicken sandwich, salted crisps and jammie dodger biscuit (54% carbohydrate, 34% fat and 12% protein). The macronutrient composition of the meals are in general agreement with guidelines recommended for a balanced diet (Public Health England, 2016). Participants will be encouraged to consume their meal within 15 minutes. The time taken will be recorded in the first condition and this time will then be replicated in the latter two conditions. Water will be available for the participants ad libitum during their first experimental condition visit. This volume of intake will be recorded and the same amount provided in the following two conditions spread over the day.

Data collection Finger prick capillary whole blood samples will be collected at baseline, 30, 60, 120, 180, 210, 240, 300 and 360 minutes throughout the conditions to allow later analysis of glucose, triglycerides, HDL-C, and insulin. Blood samples will be taken after the hand is pre-warmed in warm water for approximately 5 minutes. Blood pressure and heart rate will be measured 5 minutes before each of the blood samples are taken. Cardiac function measures and mood and wellbeing will be measured at baseline and post-condition.

02

Conditions studied

  • Cardiovascular Diseases
03

In context

Cardiovascular Diseases

5,368 studies on the registry are indexed under Cardiovascular Diseases; 939 are open to participants now.

This study's planned enrollment of 18 is below the median of 100 across 3,084 interventional studies indexed under Cardiovascular Diseases.

Browse Cardiovascular Diseases studies →

Lead sponsor

University of Bedfordshire is the lead sponsor of 12 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients post myocardial infarction (ST wave elevated MI or Non-ST wave elevated MI) within the past three months (confirmed by elevated blood biomarkers or electrocardiographic changes), in which the procedure/ recovery uncomplicated and are therefore classified as low risk.
  • Aged 40 years or above.
  • Any ethnicity.
  • Individuals with diet controlled type 2 diabetes mellitus

Exclusion criteria

Exclusion Criteria:

  • Previous MI
  • Under 40 years of age.
  • Unable to provide valid (lack of mental capacity).
  • Not had a cardiac event diagnosed within the past three months.
  • Existing comorbidities including cancer, chronic kidney disease and gastro-oesophageal diseases.
  • Unstable coronary disease.
  • Diagnosed diabetes and use of medication.
  • Disease or conditions with a prognosis of less than 6 months to end of life (palliative care). Any known blood borne disease.
  • Unable to stand and engage in light-intensity stepping.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
18 participants (estimated)

Study arms

  • Experimental
    Prolonged sitting

    Uninterrupted sitting for 6 hours.

    Behavioral: Prolonged sitting

  • Experimental
    Sitting interrupted with standing

    Sitting interrupted with 5 minutes of static standing every 30 minutes for 6 hours.

    Behavioral: Prolonged sitting

  • Experimental
    Sitting interrupted with light stepping

    Sitting interrupted with 5 minutes of light intensity stepping every 30 minutes using a metronome at the intensity determined during preliminary testing. This replicates active recovery time currently performed in a phase III CR class.

    Behavioral: Prolonged sitting

Interventions

  • BehavioralProlonged sitting

    Cross over design, where participants will take part in all three interventions listed above: 1) uninterrupted sitting, 2) sitting interrupted with standing and 3) sitting interrupted with light stepping

    Also known as: Sitting interrupted with standing, Sitting interrupted with light stepping

06

What researchers measure

Primary outcomes

  1. Posterior wall thickness

    Posterior wall thickness in cm

    Time frame: 4 months

  2. Interventricular septum

    Interventricular septum in cm

    Time frame: 4 months

  3. Left ventricular internal diameter

    Left ventricular internal diameter in cm

    Time frame: 4 months

  4. Aortic root

    Aortic root in cm

    Time frame: 4 months

  5. End volume

    End volume in cm

    Time frame: 4 months

  6. E wave

    E wave in ms

    Time frame: 4 months

  7. A wave

    A wave in ms

    Time frame: 4 months

  8. Relative wall thickness

    Relative wall thickness in cm

    Time frame: 4 months

  9. Left ventricular mass

    Left ventricular mass in g

    Time frame: 4 months

  10. E/A ratio

    E/A ratio

    Time frame: 4 months

  11. Deceleration time

    Deceleration time in ms

    Time frame: 4 months

  12. Isovolumetric relaxation time

    Isovolumetric relaxation time in ms

    Time frame: 4 months

  13. Ejection fraction

    Ejection fraction in %

    Time frame: 4 months

  14. Stroke volume

    Stroke volume in L

    Time frame: 4 months

Secondary outcomes

  1. Systolic Blood pressure

    Resting systolic blood pressure in mmHg

    Time frame: 4 months

  2. Diastolic Blood pressure

    Resting diastolic blood pressure in mmHg

    Time frame: 4 months

  3. Postprandial triglycerides

    Postprandial triglycerides in mmol/L

    Time frame: 4 months

  4. Postprandial total cholesterol

    Postprandial total cholesterol in mmol/L

    Time frame: 4 months

  5. Postprandial low density lipoprotein cholesterol

    Postprandial low density lipoprotein cholesterol in mmol/L

    Time frame: 4 months

  6. Postprandial high density lipoprotein cholesterol

    Postprandial high density lipoprotein cholesterol in mmol/L

    Time frame: 4 months

  7. Postprandial insulin

    Postprandial insulin in mU/L

    Time frame: 4 months

  8. Postprandial glucose

    Postprandial glucose in mmol/L

    Time frame: 4 months

  9. Mood and wellbeing

    Positive affect and negative affect scale. This is a 5 point score, that asks 10 questions about positive feelings and 10 questions about negative feelings. The higher the score for each scale, the more likely they are feeling positive or negative.

    Time frame: 4 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Upon registration to the study, participants will be given a unique participant ID number, which will henceforth be used in all data collection within the study. This will be determined using a number system. A confidential log will be kept by the research team to identify participants with their anonymous ID numbers, which will be encrypted on a secure computer. All other electronic documentation will also be encrypted. Only direct members of the research team will have access to the data, and will be listed on the study's delegation log. Where data is transmitted to sponsors, if necessary, it will only be identifiable by its participant ID number, thus not becoming patient identifiable at any time.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 3, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05193175
Lead sponsor
University of Bedfordshire
Responsible party
Abbie C. Bell (PhD Candidate, University of Bedfordshire) — Principal investigator
First posted
Jan 14, 2022
Start date
Nov 29, 2021
Primary completion
Apr 30, 2023 (estimated)
Completion
Jun 1, 2023 (estimated)
Last update
Mar 3, 2023

Study contacts

Abbie C Bell, MSc
Contact
abbie.bell@study.beds.ac.uk
07984545911
Joanna Richards, PhD
Contact
jo.richards@beds.ac.uk
01234400400
Joanna Richards, PhD
study director · University of Bedfordshire
Abbie C Bell, MSc
principal investigator · Bedfordshire Hospitals NHS Foundation Trust

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion